The miR-203a Regulatory Network Affects the Proliferation of Chronic Myeloid Leukemia K562 Cells.
BMI1
EGR1
K562 cells
WT1
XIAP
chronic myeloid leukemia
miR-203a
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
10
2020
accepted:
15
01
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
To study the molecular mechanism by which miR-203a affects the development of CML, bioinformatics software was used to predict the upstream transcription factors and downstream target genes of miR-203a. A 5'-rapid amplification of cDNA ends assay was performed to detect gene transcription initiation sites. A chromatin immunoprecipitation assay was used to verify the binding of transcription factors and promoter regions. A double luciferase reporter gene vector was constructed to demonstrate the regulatory effect of miR-203a on target genes. Real-time PCR and western blotting were used to detect the relative expression levels of genes and proteins, respectively. The results showed that there was a binding site for the transcription factor EGR1 in the upstream promoter region of miR-203a. WT1, BMI1, and XIAP were identified as target genes regulated by miR-203a. EGR1 and miR-203a were downregulated in human peripheral blood mononuclear cells and the CML K562 cell line, while WT1, BMI1, and XIAP were upregulated. The transcription initiation site of miR-203a was identified in the upstream promoter region (G nucleotide at -339 bp), and the transcription factor EGR1 could bind to the promoter region (at -268 bp) of miR-203a and increase its expression. Over expression of miR-203a inhibited the proliferation of K562 cells. A rescue assay showed that overexpression of WT1, BMI1, and XIAP offset the antitumor effect of miR-203a. Conclusion, EGR1 positively regulated the expression of miR-203a, thus relieving the inhibition of miR-203a on the translation of its target genes (WT1, BMI1, and XIAP) and affecting the proliferation of K562 cells.
Identifiants
pubmed: 33659248
doi: 10.3389/fcell.2021.616711
pmc: PMC7917221
doi:
Types de publication
Journal Article
Langues
eng
Pagination
616711Informations de copyright
Copyright © 2021 He, Han, An, Li, Xie, Zhou, He, Lv, He, Qu, Liu and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hematology. 2011 Mar;16(2):100-8
pubmed: 21418741
In Vitro Cell Dev Biol Anim. 2016 Sep;52(8):857-63
pubmed: 27142767
Haematologica. 2010 Aug;95(8):1325-33
pubmed: 20460641
Cell Physiol Biochem. 2018;49(4):1539-1550
pubmed: 30212824
J Cell Physiol. 2019 Aug;234(8):12404-12414
pubmed: 30609023
Exp Ther Med. 2013 May;5(5):1315-1321
pubmed: 23737871
Cancer Res. 2012 Mar 1;72(5):1051-4
pubmed: 22315347
J Cancer Sci Ther. 2015;7(2):34-43
pubmed: 26819680
Cancer Cell. 2008 Jun;13(6):496-506
pubmed: 18538733
Anticancer Agents Med Chem. 2016;16(4):414-23
pubmed: 26179263
Ren Fail. 2018 Nov;40(1):136-145
pubmed: 29532746
J Cell Mol Med. 2011 Dec;15(12):2760-7
pubmed: 21323860
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1217-21
pubmed: 25338560
Int J Lab Hematol. 2015 Aug;37(4):560-8
pubmed: 25833191
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Aug;21(4):899-904
pubmed: 23998582
Springerplus. 2016 Sep 13;5(1):1538
pubmed: 27652111
Cell Death Dis. 2019 Jan 15;10(2):35
pubmed: 30674866
Tumour Biol. 2016 Oct 14;:
pubmed: 27743381
Hematology. 2019 Dec;24(1):49-51
pubmed: 30124384
Expert Rev Mol Med. 2007 May 24;9(14):1-17
pubmed: 17524167
Leuk Res. 2013 Oct;37(10):1278-86
pubmed: 23953880
Int J Oncol. 2015 Nov;47(5):1981-8
pubmed: 26397233
J Chemother. 2006 Feb;18(1):98-102
pubmed: 16572900
PLoS One. 2011;6(11):e27804
pubmed: 22132147
Sci Rep. 2016 Jul 04;6:28301
pubmed: 27376958
Genes Chromosomes Cancer. 2018 Apr;57(4):192-202
pubmed: 29226599
Hematology. 2019 Dec;24(1):355-361
pubmed: 30880635
Oncol Res. 2018 Sep 14;26(8):1155-1165
pubmed: 28893347
Drug Dev Res. 2015 Sep;76(6):278-85
pubmed: 26284455
Front Oncol. 2019 Jun 12;9:477
pubmed: 31249806